Loading...
ECC congresses2025-01-27T17:44:34+01:00

ECC 2015 – Vienna

Medical Writer: Dr. Judith Moser

DOWNLOADS

All downloads from ECC 2015

memo_InOncology_Spezial_ECC_2015_Eng

Full report (english)

Significant therapeutic advances were also shown for the immune checkpoint inhibitors nivolumab and pembrolizumab, while new representatives of this drug class, such as atezolizumab, are well on their way. Nivolumab also excelled in the treatment of patients with small-cell lung cancer. However, the patient selection through predictive biomarkers still needs further research with regard to these novel immunotherapeutics.

Robert Pirker • MD, Medical University of Vienna, Vienna, Austria
Go to Top